Miscellaneous Topics ~ Therapy / Treatment
~ Genetics of Breast & Ovarian Cancer

All references that do not fit into, or otherwise stand apart from, the other treatment subcategories

List was last updated on Nov 16, 2019 @ 8:03 am.


    • The OncoLifeS data-biobank for oncology: a comprehensive repository of clinical data, biological samples, and the patient's perspective.
    • Sidorenkov G, Nagel J, Meijer C, Duker JJ, Groen HJM, Halmos GB, Oonk MHM, Oostergo RJ, van der Vegt B, Witjes MJH, Nijland M, Havenga K, Maduro JH, Gietema JA, de Bock GH.
    • J Transl Med. 2019 Nov 14;17(1):374. doi: 10.1186/s12967-019-2122-x.
    • Prediagnosis aspirin use, DNA methylation, and mortality after breast cancer: A population-based study.
    • Wang T, McCullough LE, White AJ, Bradshaw PT, Xu X, Cho YH, Terry MB, Teitelbaum SL, Neugut AI, Santella RM, Chen J, Gammon MD.
    • Cancer. 2019 Aug 12. doi: 10.1002/cncr.32364. [Epub ahead of print]
    • Clinical findings and outcomes of MRI staging of breast cancer in a diverse population.
    • Raghavendra A, Wecsler J, Ji L, Sheth P, Ricker C, Church T, Sposto R, Lang J, Sener S, Larsen L, Tripathy D.
    • Breast Cancer Res Treat. 2019 Apr;174(2):315-324. doi: 10.1007/s10549-018-05084-w. Epub 2018 Dec 12.
    • Review
    • Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
    • Quek RGW, Mardekian J.
    • Adv Ther. 2019 Mar;36(3):708-720. doi: 10.1007/s12325-018-0867-x. Epub 2019 Jan 17.
    • The cost of cancer care and impact of financial hardship on treatment.
    • [No author given]
    • FORCE. XRAYS. 2019 Feb 8.

    Original research:

    BRCA1 and BRCA2 Testing in Medically Underserved Medicare Beneficiaries With Breast or Ovarian Cancer.

    News: Labs, Advocacy Groups Push Back on Medicare Policy Shift on NGS Testing for Hereditary Cancer Risk. (GenomeWeb)

    News: Pricey Precision Medicine Often Financially Toxic For Cancer Patients. (Kaiser Health News)

    • Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
    • Wu L, Zhong L.
    • J Med Econ. 2019 Feb;22(2):187-195. doi: 10.1080/13696998.2018.1557199. Epub 2019 Jan 4.
    • BRCA1 deficiency and synthetic lethality in leukemias; not only gene mutation matters.
    • Piwocka K, Podszywałow-Bartnicka P, Skorski T.
    • Postepy Biochem. 2018 Oct 15;64(2):141-147.
    • BRCA2 protects mammalian cells from heat shock.
    • Nakagawa Y, Kajihara A, Takahashi A, Murata AS, Matsubayashi M, Ito SS, Ota I, Nakagawa T, Hasegawa M, Kirita T, Ohnishi T, Mori E.
    • Int J Hyperthermia. 2018 Sep;34(6):795-801. doi: 10.1080/02656736.2017.1370558. Epub 2017 Sep 10.
    • Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain.
    • Delgado-Ortega L, Ginés Rubió J, Garcías de España MDC, Carcedo D, Cordero Puentes L, Moya de Alarcón C.
    • Farm Hosp. 2018 May 1;42(3):95-102. doi: 10.7399/fh.10904.
    • A Novel Model to Characterize Structure and Function of BRCA1.
    • Lin D, Izadpanah R, Braun SE, Alt E.
    • Cell Biol Int. 2018 Jan;42(1):34-44. doi: 10.1002/cbin.10846. Epub 2017 Oct 25.
    • SMART Cancer Navigator: A Framework for Implementing ASCO Workshop Recommendations to Enable Precision Cancer Medicine.
    • Warner JL, Prasad I, Bennett M, Arniella M, Beeghly-Fadiel A, Mandl KD, Alterovitz G.
    • JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00292. Epub 2018 May 1.
    • Implementation and utilization of the molecular tumor board to guide precision medicine.
    • Harada S, Arend R, Dai Q, Levesque JA, Winokur TS, Guo R, Heslin MJ, Nabell L, Nabors LB, Limdi NA, Roth KA, Partridge EE, Siegal GP, Yang ES.
    • Oncotarget. 2017 Jun 14;8(34):57845-57854. doi: 10.18632/oncotarget.18471. eCollection 2017 Aug 22.
    • Effect of Oral Docosahexaenoic Acid (DHA) Supplementation on DHA Levels and Omega-3 Index in Red Blood Cell Membranes of Breast Cancer Patients.
    • Molfino A, Amabile MI, Mazzucco S, Biolo G, Farcomeni A, Ramaccini C, Antonaroli S, Monti M, Muscaritoli M.
    • Front Physiol. 2017 Jul 28;8:549. doi: 10.3389/fphys.2017.00549. eCollection 2017.
    • The effect of thermal dose on hyperthermia-mediated inhibition of DNA repair through homologous recombination.
    • van den Tempel N, Laffeber C, Odijk H, van Cappellen WA, van Rhoon GC, Franckena M, Kanaar R.
    • Oncotarget. 2017 Jul 4;8(27):44593-44604. doi: 10.18632/oncotarget.17861.
    • Preoperative Breast MRI: Surgeons' Patient Selection Patterns and Potential Bias in Outcomes Analyses.
    • Lee J, Tanaka E, Eby PR, Zhou S, Wei W, Eppelheimer C, Loving VA.
    • AJR Am J Roentgenol. 2017 Apr;208(4):923-932. doi: 10.2214/AJR.16.17038. Epub 2016 Dec 27.
    • Germ line mutations associated with leukemias.
    • Porter CC.
    • Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):302-308.
    • Review
    • Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125.
    • Chudecka-Głaz A, Cymbaluk-Płoska A, Luterek-Puszyńska K, Menkiszak J.
    • Oncol Lett. 2016 Nov;12(5):3101-3114. Epub 2016 Aug 29.
    • Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients.
    • Hein A, Gass P, Walter CB, Taran FA, Hartkopf A, Overkamp F, Kolberg HC, Hadji P, Tesch H, Ettl J, Wuerstlein R, Lounsbury D, Lux MP, Lüftner D, Wallwiener M, Müller V, Belleville E, Janni W, Fehm TN, Wallwiener D, Ganslandt T, Ruebner M, Beckmann MW, Schneeweiss A, Fasching PA, Brucker SY.
    • Breast Cancer Res Treat. 2016 Jul;158(1):59-65. doi: 10.1007/s10549-016-3850-8. Epub 2016 Jun 9.
    • Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing.
    • Cohen PA, Nichols CB, Schofield L, Van Der Werf S, Pachter N.
    • Int J Gynecol Cancer. 2016 Jun;26(5):892-7. doi: 10.1097/IGC.0000000000000689.
    • Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors.
    • Huang F, Goyal N, Sullivan K, Hanamshet K, Patel M, Mazina OM, Wang CX, An WF, Spoonamore J, Metkar S, Emmitte KA, Cocklin S, Skorski T, Mazin AV.
    • Nucleic Acids Res. 2016 May 19;44(9):4189-99. doi: 10.1093/nar/gkw087. Epub 2016 Feb 11.
    • Comment on 'Circulating cell-free miRNAs as biomarker for triple-negative breast cancer'-Methodological challenges in combining miRNAs as circulating biomarkers.
    • Verderio P, Bottelli S, Lecchi M, Plebani M, Gariboldi M, Pizzamiglio S, Ciniselli CM.
    • Br J Cancer. 2016 May 10;114(10):e5. doi: 10.1038/bjc.2016.1. Epub 2016 Apr 21.

    Response to: Comment on 'Circulating cell-free miRNAs as biomarker for triple-negative breast cancer'.

    • Breast cancer in a male-to-female transsexual patient with a BRCA2 mutation.
    • Corman V, Potorac I, Manto F, Dassy S, Segers K, Thiry A, Bours V, Daly AF, Beckers A.
    • Endocr Relat Cancer. 2016 May;23(5):391-7. doi: 10.1530/ERC-16-0057. Epub 2016 Mar 21.
    • Case report

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: Cancer risks for transgender patient

    • PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations.
    • Pharoah PD, Song H, Dicks E, Intermaggio MP, Harrington P, Baynes C, Alsop K; Australian Ovarian Cancer Study Group, Bogdanova N, Cicek MS, Cunningham JM, Fridley BL, Gentry-Maharaj A, Hillemanns P, Lele S, Lester J, McGuire V, Moysich KB, Poblete S, Sieh W, Sucheston-Campbell L, Widschwendter M; Ovarian Cancer Association Consortium, Whittemore AS, Dörk T, Menon U, Odunsi K, Goode EL, Karlan BY, Bowtell DD, Gayther SA, Ramus SJ.
    • J Natl Cancer Inst. 2016 Jan 27;108(3). pii: djv347. doi: 10.1093/jnci/djv347. Print 2016 Mar.
    • BRCA2-positive spinal intramedullary ovarian metastatic disease: case report.
    • Ravindra VM, Mazur MD, Driscoll M, McEvoy S, Schmidt MH.
    • Spine J. 2016 Mar;16(3):e201-7. doi: 10.1016/j.spinee.2015.10.053. Epub 2015 Nov 10.
    • Case report
    • Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia.
    • Churpek JE, Marquez R, Neistadt B, Claussen K, Lee MK, Churpek MM, Huo D, Weiner H, Bannerjee M, Godley LA, Le Beau MM, Pritchard CC, Walsh T, King MC, Olopade OI, Larson RA.
    • Cancer. 2016 Jan 15;122(2):304-311. doi: 10.1002/cncr.29615. Epub 2015 Dec 7.

    Editorial / Commentary

    Cancer susceptibility genes and their potential implication regarding systemic therapy for early-stage breast cancer.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: ATM heterozygotes and radiation

    • Management of Individuals With a Mutation in the Ataxia Telangiectasia Mutated Gene.
    • Mahon SM.
    • Oncol Nurs Forum. 2016 Jan 1;43(1):114-7. doi: 10.1188/16.ONF.114-117.
    • Review
    • Metastasis of Pregnancy-Associated Breast Cancer (Suspected to Be Hereditary Breast and Ovarian Cancer) to the Brain, Diagnosed at 18 Weeks' Gestation: A Case Report and Review of the Literature.
    • Okuda T, Yamamoto S, Matsuo S, Kataoka H, Kitawaki J.
    • Case Rep Obstet Gynecol. 2016;2016:9813253. doi: 10.1155/2016/9813253. Epub 2016 Feb 11.
    • Early Occurrence of Angiosarcoma in a Woman With a BRCA2 Gene Variation of Unknown Significance Treated With Breast-Conserving Therapy for Bilateral Ductal Carcinoma: A Case Report.
    • Parvez E, Popovic S, Elavathil L, Okawara G, Hodgson N.
    • Clin Breast Cancer. 2015 Dec;15(6):536-8. doi: 10.1016/j.clbc.2015.06.011. Epub 2015 Jun 22.
    • Case report
    • Hereditary Cancer, Insurance, and Your Legal Rights.
    • Anya Prince.
    • FORCE. Be Empowered Webinars. 2015 Nov 18.
    • First description of a sporadic breast cancer in a woman with BRCA1 germline mutation.
    • Curtit E, Benhamo V, Gruel N, Popova T, Manie E, Cottu P, Mariani O, Stoppa-Lyonnet D, Pivot X, Stern MH, Vincent-Salomon A.
    • Oncotarget. 2015 Nov 3;6(34):35616-24. doi: 10.18632/oncotarget.5348.
    • Nipple-sparing mastectomy in patients with BRCA1/2 mutations and variants of uncertain significance.
    • Manning AT, Wood C, Eaton A, Stempel M, Capko D, Pusic A, Morrow M, Sacchini V.
    • Br J Surg. 2015 Oct;102(11):1354-9. doi: 10.1002/bjs.9884. Epub 2015 Aug 27.
    • Breast cancer in pregnancy: an institutional experience.
    • Blanquisett AH, Vicent CH, Gregori JG, Zotano ÁG, Porta VG, Simón AR.
    • Ecancermedicalscience. 2015 Jul 8;9:551. doi: 10.3332/ecancer.2015.551. eCollection 2015.
    • A Rare Case of BRCA2-Associated Breast Cancer in Pregnancy.
    • Leidhin CN, Heeney A, Connolly C, Swan N, Foster A, Geraghty J.
    • Ir Med J. 2015 Jul-Aug;108(7):217-8.
    • FDA Approval — How Does it Relate to Germline Genetic Testing?
    • Laura Panos, Sara Gilvary
    • Coding Corner, Perspectives in Genetic Counseling, Volume 37, Number 2, p. 19. 2015 Qtr 2.
    • Circulating cell-free miRNAs as biomarker for triple-negative breast cancer.
    • Shin VY, Siu JM, Cheuk I, Ng EK, Kwong A.
    • Br J Cancer. 2015 May 26;112(11):1751-9. doi: 10.1038/bjc.2015.143. Epub 2015 Apr 23.
    • Regulatory Uncertainty Causing Retesting Confusion for Patients Considering New Ovarian Cancer Rx
    • Turna Ray
    • GenomeWeb, 2015 Feb 16
    • Myriad Discusses Outlook for its Burgeoning CDx Business Following Lynparza Approval
    • Turna Ray
    • GenomeWeb, 2015 Feb 4.
    • News
    • Myriad Genetics' Tumor BRACAnalysis CDx Receives CE Mark
    • GenomeWeb staff reporter
    • GenomeWeb, 2015 Jan 8.
    • Myriad, AbbVie Expand Tumor BRACAnalysis CDx Collaboration.
    • [No author given]
    • Clinical OMICs. 1(14):5. 2014 Nov 19.
    • Age-Related Decline in DNA Repair Function Explains Diminished Ovarian Reserve, Earlier Menopause, and Possible Oocyte Vulnerability to Chemotherapy in Women With BRCA Mutations.
    • Oktay K, Moy F, Titus S, Stobezki R, Turan V, Dickler M, Goswami S.
    • J Clin Oncol. 2014 Apr 1;32(10):1093-4. doi: 10.1200/JCO.2013.53.5369. Epub 2014 Feb 18.

    Chemotherapy-Induced Amenorrhea in Patients With Breast Cancer With a BRCA1 or BRCA2 Mutation.

    • XRCC1 R399Q polymorphism and risk of normal tissue injury after radiotherapy in breast cancer patients.
    • Zhou Y, Zhou W, Liu Q, Fan Z, Yang Z, Tu Q, Li L, Liu H.
    • Tumour Biol. 2014 Jan;35(1):21-5. doi: 10.1007/s13277-013-0990-x. Epub 2013 Dec 3.
    • Meta-Analysis
    • Underestimated survival predictions of the prognostic tools Adjuvant! Online and PREDICT in BRCA1-associated breast cancer patients.
    • Plakhins G, Irmejs A, Gardovskis A, Subatniece S, Liepniece-Karele I, Purkalne G, Teibe U, Trofimovics G, Miklasevics E, Gardovskis J.
    • Fam Cancer. 2013 Dec;12(4):683-9. doi: 10.1007/s10689-013-9646-7.
    • Management of breast cancer during pregnancy.
    • Rovera F, Chiappa C, Coglitore A, Baratelli GM, Fachinetti A, Marelli M, Frattini F, Lavazza M, Bascialla L, Rausei S, Boni L, Corben AD, Dionigi G, Dionigi R.
    • Int J Surg. [2013 Dec;]11 Suppl 1:S64-8. doi: 10.1016/S1743-9191(13)60020-5.
    • Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
    • Birkbak NJ, Kochupurakkal B, Izarzugaza JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC.
    • PLoS One. 2013 Nov 12;8(11):e80023. doi: 10.1371/journal.pone.0080023. eCollection 2013.
    • Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation.
    • Valentini A, Finch A, Lubinski J, Byrski T, Ghadirian P, Kim-Sing C, Lynch HT, Ainsworth PJ, Neuhausen SL, Greenblatt E, Singer C, Sun P, Narod SA.
    • J Clin Oncol. 2013 Nov 1;31(31):3914-9. doi: 10.1200/JCO.2012.47.7893. Epub 2013 Aug 26.

    Letter, Comment:

    Age-related decline in DNA repair function explains diminished ovarian reserve, earlier menopause, and possible oocyte vulnerability to chemotherapy in women with BRCA mutations.

    • The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation.
    • Valentini A, Lubinski J, Byrski T, Ghadirian P, Moller P, Lynch HT, Ainsworth P, Neuhausen SL, Weitzel J, Singer CF, Olopade OI, Saal H, Lyonnet DS, Foulkes WD, Kim-Sing C, Manoukian S, Zakalik D, Armel S, Senter L, Eng C, Grunfeld E, Chiarelli AM, Poll A, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • Breast Cancer Res Treat. 2013 Nov;142(1):177-85. doi: 10.1007/s10549-013-2729-1. Epub 2013 Oct 18.
    • Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects.
    • Henry NL, Chan HP, Dantzer J, Goswami CP, Li L, Skaar TC, Rae JM, Desta Z, Khouri N, Pinsky R, Oesterreich S, Zhou C, Hadjiiski L, Philips S, Robarge J, Nguyen AT, Storniolo AM, Flockhart DA, Hayes DF, Helvie MA, Stearns V.
    • Br J Cancer. 2013 Oct 29;109(9):2331-9. doi: 10.1038/bjc.2013.587. Epub 2013 Oct 1.
    • Breast cancer size estimation with MRI in BRCA mutation carriers and other high risk patients.
    • Mann RM, Bult P, van Laarhoven HW, Span PN, Schlooz M, Veltman J, Hoogerbrugge N.
    • Eur J Radiol. 2013 Sep;82(9):1416-22. doi: 10.1016/j.ejrad.2013.03.003. Epub 2013 Apr 6.

    Letter, Comment:

    Comparability versus statistical correctness.

    Letter, Comment:

    Good correlation does not automatically imply good agreement: the trouble with comparing tumour size by breast MRI versus histopathology.

    • A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients.
    • Chung S, Low SK, Zembutsu H, Takahashi A, Kubo M, Sasa M, Nakamura Y.
    • Breast Cancer Res. 2013;15(5):R81.
    • BRCA1/2 testing and cancer risk management in underserved women at a public hospital.
    • Hamann HA, Robinson LD, Moldrem AW, Golden EP, Mook JA, Pechero Bishop W, Sugg Skinner C, Euhus DM.
    • Commun Oncol 2012 Dec;9(12):369-376.
    • Lack of BRCA testing approval creates snag for cancer trials.
    • Azvolinsky A.
    • Nat Med. 2012 Sep 7;18(9):1310. doi: 10.1038/nm0912-1310a.
    • News
    • Breast Cancer Test Makers Will Attempt to Sway UK's NICE in Wake of Initial Negative Opinion.
    • Turna Ray.
    • Genome Web. 2012 Feb 8.

    Press: Not enough evidence for genetic breast cancer tests. (PHG Foundation)